Developments in lupus 2006

Arthritis Research and Therapy

Volumn 9, Issue 4, 2007, Pages

  Hansen, Arne ^a   Hiepe, Falk ^a,b   Dörner, Thomas ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b German Center for Rheumatology Research   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BIOLOGICAL MARKER; CD22 ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; EPRATUZUMAB; FC RECEPTOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ORAL CONTRACEPTIVE AGENT; PLACEBO; RITUXIMAB; TOLL LIKE RECEPTOR; TRIPHASIC ETHYNYL ESTRADIOL PLUS NORETHINDRONE; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; CARDIOVASCULAR RISK; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOPENIA; DISEASE ACTIVITY; DRUG FATALITY; DRUG MECHANISM; ENVIRONMENTAL FACTOR; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; HISTOPLASMOSIS; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; IMMUNOREGULATION; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; ANIMAL; DISEASE MODEL; DRUG SCREENING; GENETICS; IMMUNE SYSTEM; IMMUNOLOGY; RHEUMATOLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNE SYSTEM; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; RHEUMATOLOGY;

EID: 37849011937     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2183     Document Type: Review

References (76)

1. Wardemann H Yurasov S Schaefer A Young JW Meffre E Nussenzweig MC Predominant autoantibody production by early human B cell precursors Science 2003, 301:1374-1377. 12920303
2. Batten M Groom J Cachero TG Qian F Schneider P Tschopp J Browning JL Mackay F BAFF mediates survival of peripheral immature B lymphocytes J Exp Med 2000, 192:1453-1465. 11085747
3. Mackay F Tangye SG The role of the BAFF/APRIL system in B cell homeostasis and lymphoid cancers Curr Opin Pharmacol 2004, 4:347-354. 15251127
4. Groom J Kalled SL Cutler AH Olson C Woodcock SA Schneider P Tschopp J Cachero TG Batten M Wheway J Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome J Clin Invest 2002, 109:59-68. 150825 11781351
5. Enzler T Bonizzi G Silverman GJ Otero DC Widhopf GF Anzelon-Mills A Rickert RC Karin M Alternative and classical NF-κB signaling retain autoreactive B cells in the splenic marginal zone and result in lupus-like disease Immunity 2006, 25:403-415. 16973390
6. Dorner T Crossroads of B cell activation in autoimmunity: Rationale of targeting B cells J Rheumatol Suppl 2006, 77:3-11. 16652439
7. Ramanujam M Wang XB Huang WQ Liu Z Schiffer L Tao HO Frank D Rice J Diamond B Yu KO Similarities and differences between selective and nonselective BAFF blockade in murine SLE J Clin Invest 2006, 116:724-734. 1366500 16485042
8. Grimaldi CM Jeganathan V Diamond B Hormonal regulation of B cell development: 17β-estradiol impairs negative selection of high-affinity DNA-reactive B cells at more than one developmental checkpoint J Immunol 2006, 176:2703-2710. 16493025
9. Kuroiwa T Iwasaki T Imado T Sekiguchi M Fujimoto J Sano H Hepatocyte growth factor prevents lupus nephritis in a murine lupus model of chronic graft-versus-host disease Arthritis Res Ther 2006, 8:R123. 1779408 16859527
10. Kishimoto T Interleukin-6: Discovery of a pleiotropic cytokine Arthritis Res Ther 2006, 8(Suppl 2):S2. 16899106
11. Lipsky PE Interleukin-6 and rheumatic diseases Arthritis Res Ther 2006, 8(Suppl 2):S4. 16899108
12. Nishimoto N Kishimoto T Interleukin 6: From bench to bedside Nat Clin Pract Rheumatol 2006, 2:619-626. 17075601
13. Lenert PS Targeting toll-like receptor signaling in plasmacytoid dendritic cells and autoreactive B cells as a therapy for lupus Arthritis Res Ther 2006, 8:203. 1526546 16542467
14. Pawar RD Patole PS Ellwart A Lech M Segerer S Schlondorff D Anders HJ Ligands to nucleic acid-specific toll-like receptors and the onset of lupus nephritis J Am Soc Nephrol 2006, 17:3365-3373. 17082246
15. Lartigue A Courville P Auquit I Francois A Arnoult C Tron F Gilbert D Musette P Role of TLR9 in anti-nucleosome and anti-DNA antibody production in lpr mutation-induced murine lupus J Immunol 2006, 177:1349-1354. 16818796
16. Christensen SR Shupe J Nickerson K Kashgarian M Flavell RA Shlomchik MJ Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus Immunity 2006, 25:417-428. 16973389
17. Berland R Fernandez L Kari E Han JH Lomakin I Akira S Wortis HH Kearney JF Ucci AA Imanishi-Kari T Toll-like receptor 7-dependent loss of B cell tolerance in pathogenic autoantibody knockin mice Immunity 2006, 25:429-440. 16973388
18. Pisitkun P Deane JA Difilippantonio MJ Tarasenko T Satterthwaite AB Bolland S Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication Science 2006, 312:1669-1672. 16709748
19. Subramanian S Tus K Li QZ Wang A Tian XH Zhou J Liang C Bartov G McDaniel LD Zhou XJ A Tlr7 translocation accelerates systemic autoimmunity in murine lupus Proc Natl Acad Sci USA 2006, 103:9970-9975. 1502563 16777955
20. Ehlers M Fukuyama H Mcgaha TL Aderem A Ravetch JV TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE J Exp Med 2006, 203:553-561. 16492804
21. Nimmerjahn F Bruhns P Horiuchi K Ravetch JV FcγRIV: A novel FcR with distinct IgG subclass specificity Immunity 2005, 23: 41-51 16039578
22. Rönnefarth VM Erbacher AI Lamkemeyer T Madlung J Nordheim A Rammensee HG Decker P TLR2/TLR4-independent neutrophil activation and recruitment upon endocytosis of nucleosomes reveals a new pathway of innate immunity in systemic lupus erythematosus J Immunol 2006, 177:7740-7749. 17114445
23. Colonna L Dinnall JA Shivers DK Frisoni L Caricchio R Gallucci S Abnormal costimulatory phenotype and function of dendritic cells before and after the onset of severe murine lupus Arthritis Res Ther 2006, 8:R49. 1526610 16507174
24. Niewold TB Swedler WI Systemic lupus erythematosus arising during interferon-α therapy for cryoglobulinemic vasculitis associated with hepatitis C Clin Rheumatol 2005, 24:178-181. 15565395
25. Rönnblom L Alm GV An etiopathogenic role for the type IIFN system in SLE Trends Immunol 2001, 22:427-431. 11473831
26. Rönnblom L Alm GV Systemic lupus erythematosus and the type I interferon system Arthritis Res Ther 2003, 5:68-75. 165035 12718746
27. Hron JD Peng SL Type I IFN protects against murine lupus J Immunol 2004, 173:2134-2142. 15265950
28. Li J Liu Y Xie C Zhu J Kreska D Morel L Mohan C Deficiency of type I interferon contributes to Sle2-associated component lupus phenotypes Arthritis Rheum 2005, 52:3063-3072. 16200585
29. Feng X Wu H Grossman JM Hanvivadhanakul P FitzGerald JD Park GS Dong X Chen W Kim MH Weng HH Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus Arthritis Rheum 2006, 54:2951-2962. 16947629
30. Gottenberg JE Cagnard N Lucchesi C Letourneur F Mistou S Lazure T Jacques S Ba N Ittah M Lepajolec C Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren's syndrome Proc Natl Acad Sci USA 2006, 103:2770-2775. 1413808 16477017
31. Wenzel J Schmidt R Proelss J Zahn S Bieber T Tuting T Type I interferon-associated skin recruitment of CXCR3+ lymphocytes in dermatomyositis Clin Exp Dermatol 2006, 31:576-582. 16716166
32. Båve U Nordmark G Lövgren T Rönnelid J Cajander S Eloranta ML Alm GV Rönnblom L Activation of the type I interferon system in primary Sjogren's syndrome - a possible etiopathogenic mechanism Arthritis Rheum 2005, 52:1185-1195. 15818675
33. Farkas L Beiske K Lund-Johansen F Brandtzaeg P Jahnsen FL Plasmacytoid dendritic cells (natural interferon-α/β-producing cells) accumulate in cutaneous lupus erythematosus lesions Am J Pathol 2001, 159:237-243. 1850412 11438470
34. Barrat FJ Meeker T Gregorio J Chan JH Uematsu S Akira S Chang B Duramad O Coffman RL Nucleic acids of mammalian origin can act as endogenous ligands for toll-like receptors and may promote systemic lupus erythematosus J Exp Med 2005, 202:1131-1139. 16230478
35. Kumar KR Li L Yan M Bhaskarabhatla M Mobley AB Nguyen C Mooney JM Schatzle JD Wakeland EK Mohan C Regulation of B cell tolerance by the lupus susceptibility gene Ly108 Science 2006, 312:1665-1669. 16778059
36. Graham RR Kozyrev SV Baechler EC Reddy MV Plenge RM Bauer JW Ortmann WA Koeuth T González Escribano MF Argentine and Spanish Collaborative Groups A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus Nat Genet 2006, 38:550-555. 16642019
37. Fairhurst AM Wandstrat AE Wakeland EK Systemic lupus erythematosus: multiple immunological phenotypes in a complex genetic disease Adv Immunol 2006, 92:1-69. 17145301
38. Forabosco P Gorman JD Cleveland C Kelly JA Fisher SA Ortmann WA Johansson C Johanneson B Moser KL Gaffney PM Meta-analysis of genome-wide linkage studies of systemic lupus erythematosus Genes Immun 2006, 7:609-614. 16971955
39. Lopez P Gomez J Mozo L Gutierrez C Suarez A Cytokine polymorphisms influence treatment outcomes in SLE patients treated with antimalarial drugs Arthritis Res Ther 2006, 8:R42. 1526590 16507146
40. Freemer MM King TE Criswell LA Association of smoking with dsDNA autoantibody production in systemic lupus erythematosus Ann Rheum Dis 2006, 65:581-584. 16150789
41. Ghaussy NO Sibbitt WL Qualls CR Cigarette smoking, alcohol consumption, and the risk of systemic lupus erythematosus: A case-control study J Rheumatol 2001, 28:2449-2453. 11708417
42. Majka DS Holers VM Cigarette smoking and the risk of systemic lupus erythematosus and rheumatoid arthritis Ann Rheum Dis 2006, 65:561-563. 16611864
43. Mackay M Stanevsky A Wang T Aranow C Li M Koenig S Ravetch JV Diamond B Selective dysregulation of the FcγIIB receptor on memory B cells in SLE J Exp Med 2006, 203:2157-2164. 16923849
44. Grootscholten C Ligtenberg G Hagen EC van den Wall Bake AW de Glas-Vos JW Bijl M Assmann KJ Bruijn JA Weening JJ van Houwelingen HC Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial Kidney Int 2006, 70:732-742. 16820790
45. Tseng CE Buyon JP Kim M Belmont HM Mackay M Diamond B Marder G Rosenthal P Haines K Ilie V Abramson SB The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus - findings of a prospective, randomized, double-blind, placebo-controlled trial Arthritis Rheum 2006, 54:3623-3632. 17075807
46. Fritsch-Stork R Mullegger D Skriner K Jahn-Schmid B Smolen JS Steiner G The spliceosomal autoantigen heterogeneous nuclear ribonucleoprotein A2 (hnRNP-A2) is a major T cell autoantigen in patients with systemic lupus erythematosus Arthritis Res Ther 2006, 8:R118. 1779394 16859514
47. Kawamoto M Harigai M Hara M Kawaguchi Y Tezuka K Tanaka M Sugiura T Katsumata Y Fukasawa C Ichida H Expression and function of inducible co-stimulator in patients with systemic lupus erythematosus: Possible involvement in excessive interferon-γ and anti-double-stranded DNA antibody production Arthritis Res Ther 2006, 8:R62. 1526621 16563187
48. Hutloff A Büchner K Reiter K Baelde HJ Odendahl M Jacobi A Dörner T Kroczek RA Involvement of inducible costimulator in the exaggerated memory B cell and plasma cell generation in systemic lupus erythematosus Arthritis Rheum 2004, 50:3211-3220. 15476242
49. Iwai H Abe M Hirose S Tsushima F Tezuka K Akiba H Yagita H Okumura K Kohsaka H Miyasaka N Azuma M Involvement of inducible costimulator-B7 homologous protein costimulatory pathway in murine lupus nephritis J Immunol 2003, 171:2848-2854. 12960306
50. Yurasov S Tiller T Tsuiji M Velinzon K Pascual V Wardemann H Nussenzweig MC Persistent expression of autoantibodies in SLE patients in remission J Exp Med 2006, 203:2255-2261. 16966430
51. de Leeuw K Freire B Srnit AJ Bootsma H Kallenberg CG Bijl M Traditional and non-traditional risk factors contribute to the development of accelerated atherosclerosis in patients with systemic lupus erythematosus Lupus 2006, 15:675-682. 17120595
52. Farzaneh-Far A Roman MJ Lockshin MD Devereux RB Paget SA Crow MK Davis A Sammaritano L Levine DM Salmon JE Impact of antiphospholipid antibodies on cardiovascular disease in systemic lupus erythematosus [abstract] J Am Coll Cardiol 2006, 47(Suppl A):277A.
53. Binstadt BA Patel PR Alencar H Nigrovic PA Lee DM Mahmood U Weissleder R Mathis D Benoist C Particularities of the vasculature can promote the organ specificity of autoimmune attack Nature Immunology 2006, 7:284-292. 16444258
54. Jackson M Ahmad Y Bruce IN Coupes B Brenchley PEC Activation of transforming growth factor-β1 and early atherosclerosis in systemic lupus erythematosus Arthritis Res Ther 2006, 8:R81. 1526639 16646981
55. Ginzler EM Dooley MA Aranow C Kim MY Buyon J Merrill JT Petri M Gilkeson GS Wallace DJ Weisman MH Appel GB Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis N Engl J Med 2005, 353:2219-2228. 16306519
56. Moore RA Derry S Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis Arthritis Res Ther 2006, 8:R182. 1794528 17163990
57. Davidson A New immune modulatory drugs for systemic lupus erythematosus - what can we expect? Nat Clin Pract Rheumatol 2006, 2:638-639. 17133245
58. Isenberg DA B cell targeted therapies in autoimmune diseases J Rheumatol 2006, 33(Suppl 77):24-28. 16652442
59. Dorner T Lipsky PE Signalling pathways in B cells: Implications for autoimmunity Curr Concepts Autoimmun Chron Inflamm 2006, 305:213-240.
60. Baker KP Edwards BM Main SH Choi GH Wager RE Halpern WG Lappin PB Riccobene T Abramian D Sekut L Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator Arthritis Rheum 2003 48 3253 3265 14613291
61. Halpern WG Lappin P Zanardi T Cai W Corcoran M Zhong J Baker KP Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects Toxicol Sci 2006, 91:586-599. 16517838
62. Ng KP Leandro MJ Edwards JC Ehrenstein MR Cambridge G Isenberg DA Repeated B cell depletion in treatment of refractory systemic lupus erythematosus Ann Rheum Dis 2006, 65:942-945. 16269424
63. Radbruch A Muehlinghaus G Luger EO Inamine A Smith KG Dörner T Hiepe F Competence and competition: The challenge of becoming a long-lived plasma cell Nat Rev Immunol 2006, 6:741-750. 16977339
64. Sfikakis PP Boletis JN Lionaki S Vigklis V Fragiadaki KG Iniotaki A Moutsopoulos HM Remission of proliferative lupus nephritis following anti-B cell therapy is preceded by downregulation of the T cell costimulatory molecule CD40-ligand Arthritis Rheum 2004, 50(Suppl):S227.
65. Vigna-Perez M Hernandez-Castro B Paredes-Saharopulos O Portales-Perez D Abud-Mendoza C Gonzalez-Amaro R Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: A pilot study Arthritis Res Ther 2006, 8:R83. 1526618 16677395
66. Cambridge G Leandro MJ Teodorescu M Manson J Rahman A Isenberg DA Edwards JC B cell depletion therapy in systemic lupus erythematosus - effect on autoantibody and antimicrobial antibody profiles Arthritis Rheum 2006, 54:3612-3622. 17075806
67. Wallerskog T Zhou W Wohren-Herlenius M Klareskog L Malmstrom V Trollmo C Increased Baff levels after rituximab-induced B-cell depletion in SLE patients Clin Immunol 2006, 119:S63.
68. Collins CE Gavin AL Migone TS Hilbert DM Nemazee D Stohl W B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: Disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels Arthritis Res Ther 2006, 8:R6. 1526545 16356193
69. FDA Public Health Advisory: Life-threatening brain infection in patients with systemic lupus erythematosus after Rituxan (rituximab) treatment http://www.fda.gov/cder/drug/advisory/rituximab.htm
70. Dorner T Kaufmann J Wegener WA Teoh N Goldenberg DM Burmester GR Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus Arthritis Res Ther 2006, 8:R74. 1526638 16630358
71. Stein R Cardillo TM Qu Z Hansen HJ Goldenberg DM Anti-lymphoma effects and mechanisms of action of epratuzumab in cell lines and human xenografts Cancer Biother Radiopharmaceut 2006, 21:404-405.
72. Petri M Kim MY Kalunian KC Grossman J Hahn BH Sammaritano LR Lockshin M Merrill JT Belmont HM Askanase AD Combined oral contraceptives in women with systemic lupus erythematosus N Engl J Med 2005, 353:2550-2558. 16354891
73. Bootsma H Spronk P Derksen R de Boer G Wolters-Dicke H Hermans J Limburg P Gmelig-Meyling F Kater L Kallenberg C Prevention of relapses in systemic lupus-erythematosus Lancet 1995, 345:1595-1599. 7783536
74. Hiepe F Manz RA Radbruch A The role of long-lived plasma cells in autoimmunity Ann Rheumatic Dis 2004, 63:16-17.
75. Hoyer BF Manz RA Radbruch A Hiepe F Impact of cellular therapies on autoreactive, long-lived plasma cells in autoimmune diseases Bone Marrow Transplant 2004, 33:S26.
76. Loh Y Oyama Y Statkute L Quigley K Yaung K Gonda E Barr W Jovanovic B Craig R Stefoski D Development of a secondary autoimmune disorder after hematopoeitic stem cell transplantation for autoimmune diseases: Role of conditioning regimen used Blood 2007, 109:2643-2648. 17119125